TCT-155 A Novel Multi Lumen Compliant Balloon Catheter (ND® Infusion Catheter) Preserves Stem Cell Viability and Improves Dispersion When Compared to a Standard Single Lumen Balloon Angioplasty Catheter  by Dib, Nabil et al.
Segment Variable SC Placebo p value
Culprit stented segment D MLA (mm2) -1.2 [-3.0, -0.2] -1.5 [-3.2, -0.1] 0.97
% NIH volume (%) 12.1 [3.7, 29.8] 7.6 [3.5, 30.6] 0.95
D Maximum arc of attenuated plaque ( ) 1.0 [-3.6, 9.0] -12.4 [-25.0, -3.7] 0.004
Culprit proximal 5mm
reference segment
D MLA (mm2) -1.2 [-2.7, -0.7] -0.7 [-1.2, -0.5] 0.19
D% plaque volume (%) 3.3 [0.6, 8.3] 3.1 [-2.7, 7.0] 0.41
Culprit distal 5mm
reference segment
D MLA (mm2) 0.0 [-1.5, 0.2] -0.1 [-0.2, 0.4] 0.72
D% plaque volume (%) 3.9 [0.3, 8.3] 0.6 [-2.1, 5.2] 0.19
Proximal non-culprit
segment in culprit vessel
D MLA (mm2) -0.4 [-0.8, -0.1] -0.6 [-1.2, 0.5] 0.69
D% plaque volume (%) 0.8 [-1.9, 2.7] -0.5 [-3.5, 2.9] 0.53
Distal non-culprit segment
in culprit vessel
D MLA (mm2) -0.2 [-0.7, 0.4] -0.1 [-0.7, 0.6] 0.97
D% plaque volume (%) -1.1 [-2.7, 0.0] -0.8 [-2.5, 2.4] 0.50
Non-culprit segment in
non-culprit vessel
D MLA (mm2) -0.2 [-0.7, 0.1] 0.2 [-0.1, 0.6] 0.10
D% plaque volume (%) 0.6 [-1.9, 2.1] -1.4 [-2.0, 1.3] 0.50
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ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration
(ALLSTAR): The Six Month Phase I Safety Results
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Background: In CADUCEUS, autologous cardiosphere-derived cells decreased infarct
size and increased viable tissue in post-MI patients. The ﬁrst-in-human Phase I
ALLSTAR trial was designed to test the safety and feasibility of intracoronary infusion
of allogeneic cardiosphere-derived cells (CAP-1002) in patients with a previous anterior
myocardial infarction (MI), within the prior 12 months with scar size >15% by MRI.
Methods: A total of 14 adult subjects (mean age ¼ 55.6 yr; range 40-66 years) with a
recent (28 – 90 days; n¼9) or chronic (91-365 days; n¼5) anterior wall MI (mean infarct
size 25.4%; range 15.3% – 32.7%) and LV dysfunction (mean LVEF 42%; range 26.7%
- 55.1%) were prospectively enrolled and infused with CAP-1002 (n¼4 at 12.5M dose;
n¼10 at 25Mdose) via stop-ﬂow intracoronary infusion. Primary safety endpoints were:
MACE events (recurrent MI, hospitalization or ER treatment for heart failure, LVAD
placement or heart transplantation), acute myocarditis, death due to arrhythmias or
unwitnessed death in persons otherwise well. Humoral and cellular immunologic re-
sponses were assessed via single antigen bead and ELISpot assays.
Results: No pre-speciﬁed safety endpoint occurred. Only two adverse events were
treatment-related, both transient hypotension related to nitroglycerin. There were no
clinically signiﬁcant rises in peri-procedural cardiac enzymes. Donor speciﬁc anti-
bodies (DSAs) were present in four subjects prior to infusion; one resolved and three
persisted during 6 months of follow up. De novo DSA’s developed in four subjects,
three resolved during follow up and one persisted at 6 months of follow up. All DSA
levels observed were low (MFI< 5000). ELISpot revealed no de novo cellular
immune responses.
Conclusions: Intracoronary infusion of allogeneic cardiosphere-derived cells (CAP-
1002) appears to be safe and feasible. On the basis of the present ﬁndings, the
ALLSTAR trial has proceeded to a Phase II randomized, double-blind component,
powered to assess reduction of scar size by MRI.
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Safety and efﬁcacy of transendocardial injection of mesenchymal and induced
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Background: Mesenchymal stem cells (MSC) are the most promising cells for
ischemic myocardial repair. Nowadays we can obtain them from induced pluripotent
stem cells (iPS). Our objective is to compare the safety and efﬁcacy of “conventional”
MSC and iPS-derived MSC in a large animal model of myocardial ischemia.
Methods: Phase I/II preclinical randomized, placebo-controlled trial, with 30 large
white pigs included. Acute myocardial infarction (AMI) will be created after 90-min
occlusion of the LAD. The 3 groups are: injection of 20x106 MSC from human ad-
ipose tissue (n¼10); injection of 20x106 MSC from human iPS (n¼10); injection of
saline (n¼10). Injections will be performed in the scar border with the NOGA XP
platform, 7 days after AMI. Safety endpoints include MACE, malignant arrhythmias
and lab parameters (intraprocedural and for 5 weeks). Efﬁcacy endpoints include scar
size and LV parameters (MRI) and myocardial repair by histology (ﬁbrosis and
capillary density, staining with human nuclear antibodies) at 5 weeks.Results: So far 10 pigs have been included, weight 34.86.2 kg. Troponin and CPK
values (mg/L) were preinjection 0.41 0.61 and 4.73.0, and postinjection 0.440.33
and 8.65.1, respectively. Cell injection was successful in all cases, with 1 episode of
ventricular ﬁbrillation successfully cardioverted and no other events during the
procedures or in the follow-up.B46 JACC Vol 64/11/Suppl B j SeConclusions: This is the ﬁrst stem cell study designed to assess the cardiac repair
ability of iPS-derived MSC. NOGA-guided injections 7 days after AMI were safe. No
efﬁcacy data are available, but will be during the conference.
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Impact of Intracoronary Injection of CD133+ Bone Marrow Stem Cells on
Coronary Atherosclerotic Progression in Patients with STEMI:
A COMPARE-AMI IVUS Substudy
Fuyu Qiu1, Akiko Maehara2, Ramez El Khoury3, Philippe Genereux4, Laura LaSalle5,
Gary S. Mintz6, Nicolas Noiseux7, François Gobeil7, Louis-Mathieu Stevens7,
Francois Reeves8, Alain Rivard9, Samer Mansour10
1Cardiovascular Research Foundation and Columbia University Medical Center,
New York, NY, 2Cardiovascular Reserach Foundation and Columbia University
Medical Center, New York, United States, 3Centre Hospitalier de l’Université de
Montréal, Montreal, Quebec, 4Columbia University Medical Center, New York,
United States, 5Cardiovascular Research Foundation, New-York, NY,
6Cardiovascular Research Foundation, Washington, United States, 7University of
Montreal, Montreal, Quebec, 8CHUM, Montreal, Quebec, 9CHUM, Montreal,
Québec, 10Centre Hospitalier de l’Universite de Montreal, Montreal, Canada
Background: COMPARE-AMI was a randomized, prospective, double-blind, single-
center trial to investigate the effect of an intracoronary injection of CD133+ bone
marrow stem cells (SC) vs placebo (Placebo) on infarcted myocardium in pts with ST-
segment elevation myocardial infarction (STEMI) who underwent primary percuta-
neous coronary intervention. This IVUS substudy sought to evaluate the adverse effect
of CD133+ bone marrow stem cells onto the progression of coronary artery disease in
the stented, non-stented segment of culprit vessel, and non-culprit vessels.
Methods: Baseline and 4-month follow-up IVUS images were obtained in 17 SC and
20 Placebo pts. In culprit vessels stented and 5mm proximal and distal reference
segments, and proximal and distal non-stented segments were analyzed every 1mm; in
non-culprit vessels the entire segments were analyzed every 1mm.
Results: In the culprit vessel analysis, in-stent median % neointimal hyperplasia (NIH)
(¼NIH/stent volume) (12.1%vs 7.6%, p¼0.95), reduction ofminimal lumen area (MLA)
(-1.2 mm2 vs -1.5 mm2, p¼0.97), andMLA at follow-up (4.3mm2 vs 5.3mm2, p¼0.22)
were similar between SC and Placebo. Changes in proximal and distal non-stented
segment lumen areas and %plaque volume (¼plaque/vessel volume) were also similar
between SC and Placebo pts. However, there was a decrease in the maximum arc of
attenuated plaque behind the stent frombaseline to follow-up in Placebo, but not in SC pts
(-12.4 vs. 1.0, p¼0.004). In the non-culprit vessel analysis, there were no differences in
changes of MLA, %plaque volume, or attenuated plaque between SC and Placebo pts.
Conclusions: CD133+ bone marrow stem cells (SC) injection through the coronary
artery has no effect on disease progression in both culprit and non-culprit vessels.TCT-155
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Nabil Dib1, John P. Abraham2, Brian D. Plourde2, Dillon Schwalbach2,
DeAnn Dana3, Lester Myers4, Katherine Hunkler4, Siddharth R D’Silva3,
Todd R. Flower5, Robert E. Kohler3
1Mercy Gilbert Medical Centers/Dignity Health, Gilbert, United States, 2University of
St Thomas, St Paul, MN, 3Translational Research Institute, Gilbert, AZ, 4Celebration
Stem Cell Centre, Gilbert, AZ, 5Celebration Stem Cell Center, Gilbert, AZ
Background: Intracoronary infusion of stem cells (SC) is typically administered
through a single lumen balloon angioplasty catheter (SLC). These catheters are not
optimized for SC delivery and potentially compromise SC viability and effectiveness.
A multi-lumen catheter (MLC), (ND Infusion Catheter, Translational Research
Institute Gilbert, AZ) may preserve cell viability (CV) and improve dispersion.
Methods: A standard .014” over the wire SLC was compared to a novel MLC 3 Fr.
014” rapid exchange catheter with 6 micro-lumens that act as cell separators.ptember 13–17, 2014 j TCT Abstracts/Cell Therapy and Angiogenesis
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CV at infusion rates of 1ml/minute at various balloon inﬂations (BI). Mesenchymal
SC at concentration of 5x106/ml were tested for viability using trypan blue pre and
post injection through the SLC and MLC during BI of 6, 8, 10 and 12 atm. Numerical
modeling was used to determined ﬂuid dispersion at different ﬂuid velocities,
viscosities and exit distances.
Results: Collapsing of the SLC infusion lumen was noted during BI while no changes
were noted in the MLC infusion lumen. Computational ﬂuid dynamic calculations in
the SLC demonstrated signiﬁcant increase of 2979 Pascal in ﬂuid shear stress. As
balloon pressure increased in the SLC, the infusion lumen collapsed, whereas ﬂuid
shear stress in the MLC was 43 Pascal. CV decreased in the SLC at a ﬂow rate of
1ml/min from (97.5 to 91.7)%, (95.7 to 94.1)%, (94.9 to 86.8)%, (97.9 to 76.9)% at
6, 8, 10 and 12 atm respectively (p¼0.047) while no signiﬁcant change in CV
occurred using MLC resulting in (93.5 to 92.3)%, (95 to 93.1)%, (95 to 94.6)%, (93.2
to 97.3)% at 6, 8, 10, 12 atm respectively (p¼0.897). A computational model revealed
the MLC reduced hydraulic resistance to blood ﬂow by approximately 8% - 12% and
increased ﬂuid dispersion compared to the SLC.
Conclusions: A novel multi-lumen catheter may improve stem cell delivery by
preserving cell viability while improving dispersion.
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Different Dose of Stem Cells Transplantation in patients with Acute Myocardial
Infarction: a Meta-analysis
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Background: To evaluate whether stem cells transplantation improves global left
ventricular ejection fraction (LVEF) in patients with acute myocardial infarction(AMI)
and ﬁnd the most suitable dose to improve cardiac function.
Methods: Electronic searches include MEDLINE, The Cochrane Library, Embase,
CINAHL, CNKI and CBM, which retrieval time limit is from January 1990 to March
2014, unlimited practice. According to cell dosage and follow-up time, all trials were
divided into four or three subgroups. Data were analysed quantitatively using RevMan
5.2.Summary results are presented as weighted mean difference (WMD) with 95%
conﬁdence interval (CI). Collected individual trials data and undertook a meta-anal-
ysis to compare global Left Ventricular Ejection Fraction (LVEF).
Results: 33 papers (included 38 RCTs) were included in this study. The global LVEF
was obviously higher in stem cells transplantation group than control group(P <
0.0001). Subgroup analysis showed thatDLVEF in the dose of BMCs between 10 to the
8th power and 10 to the 9th power were signiﬁcantly higher than that in the control
groups (p< 0.05), which suggested that the global LVEF could improved after BMCs
therapy when the dose of BMSc in a certain range.When subgroups were in accordance
with the follow-up time, the results showed that with follow-up time prolonging, LVEF
was continuing to increase, and that persisted for more than 12 months (p< 0.01).
Conclusions: Stem cell transplantation after acute myocardial infarction could improve
the global LVEF in AMI patients. It may be effective when the dose of stem cells is
108-109. And the improvement of cardiac function would last more than 12 months.
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Insulin enhances dendritic cells scavernger receptor-mediated endocytic uptake
of oxLDL
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Background: The prevalence of atherosclerotic cardiovascular disease is higher in pa-
tients with type 2 diabetes, a disorder characterized by hyperinsulinemia and insulin
resistance. The role of hyperinsulinemia as an independent participant in the atherogenic
process has been controversial. Therefore, we examined whether insulin could regulate
the expression of scavenger receptors responsible for oxidised low-density lipoprotein
(oxLDL) uptake in DCs, a critical step in atherogenesis. In addition, we investigated the
impact of insulin onDCmaturation regardingchanges inphenotype and cytokine secretion.
Methods: Immature DCs were cultured with different concentrations of insulin
(1nmol/L, 10nmol/L, 100nmol/L) in the absence or presence of LY294002 or wart-
mannin for 24 hours. The expression of the scavenger receptors SR-A and CD36 was
determined by real-time PCR and western blot analysis. Furthermore, DCs were
incubated with DiI-labelled oxLDL. The DiI-oxLDL-incorporated fraction was
investigated by ﬂow cytometry analysis. Finally, ﬂow cytometry analysis was used to
investigate immunophenotypic protein expression (CD83 and CD11a). DC-differen-
tiation was evaluated using the expression of BDCA-1/-2 by ﬂow cytometer analysis.
Supernatant cytokine measurements were used for immune function assays.
Results: The incubation of DCs with insulin enhanced, in a dose-dependent manner,
the gene and protein expression of SR-A and CD36. This effect was partially abol-
ished by wartmannin, a phosphatidylinositol-3-OH kinase(PI3 kinase) inhibitor. But
LY294002 did not inhibit the effect of insulin on scavenger receptors’ expression.
High concentration of insulin increased the oxLDL-uptake capacity of DCs. Blockage
of the scavenger receptors SR-A and CD36 signiﬁcantly reduced oxLDL uptake.
Furthermore, high concentration of insulin induced DC-maturation and triggeredJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Codifferentiation of DCs in myeloid and plasmacytoid DCs. Finally, high concentration
of insulin decreased IL-10 secretion and increased IL-6 release.
Conclusions: This study suggests that hyperinsulinemia could promote DC activation
and oxLDL uptake and thus may contribute to atherosclerosis in patients with type 2
diabetes.Congenital Heart Disease - PFO and ASD
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Assessment Of Sleep Apnea In Patients With And Without A Patent Foramen
Ovale
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Background: Obstructive sleep apnea (OSA) is a medical condition associated with
increased risk of cardiovascular mortality. It is reported that the prevalence of patent
foramen ovale (PFO) is increased in patients with OSA and may be involved in the
pathophysiology of OSA in some patients. The aim of this study was to assess the
presence of PFO in patients with OSA, and compare clinical characteristics and
parameters of the sleep studies of patients with and without PFO.
Methods: Patients with an abnormal polysomnogram seen at UCLA-Santa Monica
Sleep Medicine Clinic from January 2011 to September 2013 were enrolled in the
study. PFO diagnosis was made using transcranial Doppler (TCD) with an agitated
saline bubble study; a Spencer grade  3 was considered positive. Control subjects
were drawn from the population of patients referred for cardiac catheterization at the
UCLA Cardiac Catheterization Laboratory who underwent TCD. The frequency of
right-to-left shunt (RLS) in patients with OSA and the control group was evaluated.
The clinical characteristics and parameters of the polysomnogram were compared
between OSA patients with and without RLS.
Results: A total of 100 subjects with sleep apnea and 200 control patients participated
in the study. The prevalence of RLS was higher in patients with OSA than in the
control group (42% vs. 19%; p< 0.0001). When comparing patients with OSA, those
with PFO had a lower apnea hypopnea index (AHI) and fewer obstructive apnea and
hypopnea episodes. However, the baseline and nadir SaO2 were similar in both groups
and did not correlate with the level of RLS assessed by TCD.
Conclusions: PFO is found 2.2 times as frequently when patients have OSA
compared to a control population that was not tested for OSA. The severity of the
sleep apnea is not greater in the patients with OSA and PFO as evident by fewer apnea
and hypopnea episodes. But people who have OSA and a PFO are more likely to
become symptomatic earlier with an equivalent level of decrease in SaO2 which
would explain the increased prevalence of PFO in the pool of patients with OSA.
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Background: Orthodeoxia-platypnea syndrome (OPS) is a rare clinical condition
characterized by hypoxemia in the upright position that is improved in the supine po-
sition. Although several etiologies of OPS exist, it is frequently associated with right-to-
left shunting of blood at the cardiac or pulmonary level, usually via a patent foramen
ovale (PFO). The aim of this study was to describe the outcomes of PFO closure in OPS.
Methods: Patients with OPS and a PFO referred to UCLA from 2001 to 2012 who
elected to have their PFO closed were assessed for the severity of their symptoms and
interval SaO2 changes, and classiﬁed according to the outcomes of “resolved,”
“improved” or “no change.” The results were compared between the three groups.
Results: Of 683 patients with PFO-associated conditions, 17 (2.5%) had OPS and
elected to close their PFO. Approximately a third of patients experienced complete
resolution of their dyspnea and hypoxemia, requiring no supplemental oxygen use
(improved SaO2 from baseline 8.5% when recumbent and 26% when upright; p¼0.03
and p< 0.0007 respectively). Another third experienced signiﬁcant improvement in
dyspnea, with baseline SaO2 improved to >93% and a smaller decrease in saturation
on sitting upright; they continued using supplemental oxygen (improved SaO2 from
baseline 4% when recumbent and 11% when upright, p¼0.29; p¼0.05 respectively).
Patients with no change after PFO closure predominantly had a pulmonary etiology
for their hypoxia, with elevated mean pulmonary pressures measured before closure
(51.416.8 mmHg, p¼0.06).ngenital Heart Disease - PFO and ASD B47
